RMH - CAR-T Treatment
key details
| Status | complete |
|---|---|
| Procedure | direct |
| SME suitable | Yes |
| OCID | ocds-h6vhtk-05d335 |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| not named | £380,000 | · | pending |
description
CAR-T treatment called Obecel developed to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL) which has recently become available to patients. The decision which treatment is most suitable applicable to a specific age group is a clinical one that would be decided by a Multi-Disciplinary Team (MDT). The product should meet strict NHS England standards for cryogenic storage and handling and RMH has such credentials.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 24 Oct 2025 | Transparency notice (UK5) | Procurement Act 2023 | 068116-2025 |
more from The Royal Marsden NHS Foundation Trust
- RMH - Fire Detection / Suppression / Maintenance · 26 Jun 2026
- MMprofiler · 17 Jun 2026
- EuroClonality-NDC panel · 15 Jun 2026
- Validation of Pharmacy Aseptic Unit · 26 Mar 2026
- RMH - Radiopharmaceuticals Xiel · 12 Mar 2026
- RMH - ACE PCR reagent rental · 23 Feb 2026
- RMH Radiopharmaceuticals GE · 17 Feb 2026
- PET-CT FDG tracers for Private patients · 11 Feb 2026
all contracts from this buyer →
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.